TSVT - Stock Analysis & Overview

About 2seventy bio, Inc.

Biotechnology

Healthcare

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

2seventy bio, Inc. Key Metrics

Market Cap: $252M
52 Weeks Low: $1.54
52 Weeks High: $6.40
P/B: 1.09x
P/E: -1.64x
P/S: 5.72x

Upcoming Events

TSVT Analyst Forecasts

‌

TSVT Financials

TSVT Income Statement Key Metrics

Revenue(TTM)44.12 M
Gross Profit(TTM)21.25 M
EBITDA(TTM)-155.84 M
Net Income(TTM)-156.25 M
EPS Diluted(TTM)-3.0700000000000003

Decode TSVT's Latest Earnings Call with Ease

Tap 'Generate' for a crystal-clear,
AI-crafted summary and stay ahead in the investment game!

TSVT earnings and revenue history

Gross Profit Margin vs Peers

Profit margin ratio of TSVT (0.729) is higher than the average of its peers (-1.060).

Net Profit Margin vs Peers

Net profit margin ratio of TSVT (-2.167) is higher than the average of its peers (-47.815).

TSVT Return on Equity

See how efficiently TSVT generates profit for it's shareholders.

-85.22%

100

Poor

Average

Strong

Return on Equity vs Peers

Return on Equity ratio of TSVT (-0.852) is lower than the average of its peers (-0.295).

Return on Equity Growth

TSVT's Return on Equity has shown poor growth over the past 10 years, increasing by only -24.42%.

TSVT Revenue Growth

See how TSVT has grown it's revenue over the past 10 years.

‌

Revenue Growth

TSVT's revenue has grown significantly over the past 10 years, increasing by over 10.69%.

2seventy bio, Inc.

Page title

Section title